Thursday, November 19, 2026

Subscribe

NewsEdition DR CongoDR Congo

In DR Congo, Ervebo protects health workers, but its effectiveness against Bundibugyo Ebola remains unproven

The Democratic Republic of the Congo is using Ervebo to protect health workers exposed to Bundibugyo Ebola, despite a lack of evidence that it works against this strain. A clinical trial will assess its protection, while supportive care remains essential.

Congolese health workers gathered for an Ebola vaccination session at a health centre in Beni

Vaccinating health workers against Ebola when the vaccine’s protection remains uncertain: in the Democratic Republic of the Congo, the decision addresses an immediate need. In affected areas, every exposed health professional can also become an essential link in the response.

The vaccine being used, Ervebo, has proved effective against the Zaire strain of the Ebola virus. But the current outbreak is caused by Bundibugyo, a different strain. Health authorities are considering the possibility of cross-protection, but cannot yet confirm it in humans.

Possible protection, not a guarantee

In Beni, in the east of the country, health workers and other frontline responders have received Ervebo under compassionate use. This arrangement allows a product to be used in a serious situation, even if its approval does not specifically cover the disease in question.

The distinction matters. Ervebo is approved against the disease caused by the Zaire virus. For Bundibugyo, the available data do not allow anyone to claim that it prevents infection or severe illness. The World Health Organization (WHO) says laboratory results and animal studies suggest possible protection, but that its effectiveness in humans remains unknown. The WHO and the Africa Centres for Disease Control and Prevention announced in August the allocation of 70,000 doses to the DRC.

The announced distribution provides for about 50,000 doses for health professionals and other people mobilised on the ground. The remaining 20,000 are to be used in a clinical trial to assess protection against Bundibugyo. The protocol is intended to produce stronger evidence than extrapolation from another strain.

Vaccination therefore does not replace protective equipment, screening or the isolation of cases. It is an additional measure, in a context where teams must limit risks while continuing routine care.

Care beyond the vaccine

In the absence of a vaccine or treatment specifically approved against Bundibugyo, supportive care remains crucial. This includes correcting dehydration, treating certain associated infections, administering oxygen or giving a patient a blood transfusion when their condition warrants it.

WHO Regional Director for Africa Mohamed Janabi has stressed that these interventions can improve the chances of survival. He also reported 2,400 survivors during this outbreak. This figure should be put in context: totals change rapidly and do not necessarily describe the latest situation.

The Congolese health ministry had recorded 9,066 confirmed cases and 4,381 deaths in data released before this update. A tally published on 13 October by the Associated Press, citing the authorities, said the number of confirmed cases had exceeded 9,000 and deaths 4,300. These figures show the scale of the outbreak, but should not be confused with a final tally.

Declared on 15 May 2026, the DRC’s 17th Ebola outbreak is caused by the Bundibugyo virus. It was initially concentrated in Ituri, in the north-east, before spreading to other provinces. The WHO has also reported cases in Uganda and classified the event as a public health emergency of international concern. Its epidemiological monitoring highlights the need for coordination between the two countries.

Response hampered by movement and insecurity

The health response is taking place in difficult conditions. Insecurity makes it harder to reach some communities. Population movements complicate contact tracing. A strike by health professionals and high levels of movement can also disrupt care and surveillance.

These obstacles do not affect everyone in the same way. Medical teams face direct exposure to the virus and sometimes have to work with limited resources. For people in rural or remote areas, reaching a health centre quickly can be more difficult than in major urban centres. Conversely, travel between cities and provinces increases the need for coordination and follow-up.

The authorities have also emphasised early care. Prompt treatment can address complications and support the body, even though it is not a specific cure for Bundibugyo. The capacity of centres to admit patients, protect staff and maintain communities’ trust therefore remains central.

An issue that extends beyond the DRC’s borders

Ituri’s proximity to Uganda gives the response a regional dimension. The two countries must share alerts, organise border surveillance and coordinate follow-up of exposed people. African health authorities and the WHO are involved in this effort, while data from the Ervebo trial could inform future responses to this strain.

The DRC is also a member of the Southern African Development Community, or SADC, and the East African Community, or EAC. In this emergency, health cooperation with Uganda and continental mechanisms, particularly Africa CDC, is especially direct. The outbreak is a reminder that viruses do not follow administrative borders and that regional preparedness must rely on laboratories, teams and alert systems able to work together.

The next challenge will be to document the results of vaccination without attributing to it an effectiveness against Bundibugyo that has not yet been demonstrated. At the same time, access to care, the protection of responders and the monitoring of transmission clusters will determine the ability to curb the outbreak. For the Congolese, the immediate promise therefore does not lie in a vaccine alone, but in a response combining prevention, reliable data and accessible care.

Automatic translation. Original French version

News quiz

Edition DR CongoDR Congo: the news quiz for 14–15 November

5 questions